51 results about "Vaginal ring" patented technology

The present invention provides improved sustained release formulations of estradiol metabolites, including 2-hydroxyestradiol, 2-methoxyestradiol, 4-hydroxyestradiol and 4-methoxyestradiol, useful for therapeutic treatments. The invention also provides methods of producing sustained release forms of estradiol metabolites. The compositions of the present invention include microparticles, nanoparticles, patches, crystals, gels, rods, stints, pallets, discs, lozenges, wafers, capsules, films, microcapsules nanocapsules, hydrogels, liposomes, implants and vaginal rings. Compositions also include formulations for transdermal and intravenous delivery of estradiol metabolites. The present invention provides numerous improvements over previous forms of estradiol metabolites, such advantages including the sustained release of normally short half-life compounds to maintain therapeutic blood levels.

The invention relates to a preparation method for two types of slow-release mifepristone vaginal ring preparations. The first type of slow-release mifepristone vaginal ring preparation includes from 1.0 to 4.5 wt% of mifepristone, from 1.5 to 13.5 wt% of drug scattered carrier, from 0.05 to 20 wt% of surfactant and from 62 to 97.45wt% of medical high polymer release control materials. The second type of slow-release mifepristone vaginal ring preparation includes from 1.0 to 4.5 wt% of mifepristone, from 1.5 to 13.5 wt% of drug scattered carrier, from 0.05 to 20 wt% of surfactant, from 62 to 97.45wt% of medical high polymer release control materials, and a thin release control membrane covered on the outside of each slow-release mifepristone vaginal ring preparation. Due to the preparation method, a slow-release mifepristone vaginal ring can slowly release the mifepristone within seven days, a first pass effect and gastrointestinal reaction of mifepristone orally taken drug are avoided, bioavailability of the drug and pharmacy compliance of a patient are improved.

A vaginal ring sensor device adapted to be placed within the vaginal vault of a user, the device including a ring body, at least one through hole that passes through the ring body, and at least one biosensor structured and arranged to sense and/or measure a parameter of vaginal fluid as such fluid passes through the at least one through hole.

A method of birth control and hormone regulation comprises utilizing a vaginal ring worn continuously during each menstrual cycle. A vaginal ring delivers predetermined doses of progesterone and beta-estradiol. Beta-estradiol does not cause an increase in sex hormone binding globulin and thereby does not decrease a woman's levels of free testosterone and libido.

The invention relates to mifepristone shell-type vaginal ring preparation and application. A miferprisone shell-type vaginal ring comprises, by weight, 1.0-6.0% of mifepristone, 0.5-3.0% of medicine dispersion carriers, 0.3-2.0% of additives and 89.0-98.2% of medical polymer controlled release materials. Firstly, a solid dispersion technology is adopted for improving the solubility in water and release degree in vitro of the mifepristone, then a method of mold pressing vulcanization forming is adopted for preparing the mifepristone shell-type vaginal ring, the inner layer is a vacancy silicon rubber skeleton layer, the middle is a medicated layer, and the outmost layer is a controlled release film. By the implementation of the mifepristone shell-type vaginal ring preparation and application, the vaginal ring can release the mifepristone within 21 days at almost constant speed slowly and continuously for a long time, so that the medicine can be released more stably, the first-pass effect and gastrointestinal reaction caused by oral medication of the mifepriston are avoided, and the biological availability of the medicine and medication compliance of a patient are improved. The vaginal ring can be used for routine contraception and treating gynecological diseases such as the endometriosis and the uterine fibroid.

The invention provides anti-HPV type vaginal temperature-sensitive gel, a preparation method and application thereof. The temperature-sensitive gel includes poloxamer, chitosan, chlorhexidine gluconate, giant salamander oligosaccharide peptides, recombinant human interferons and cell growth factors at the specific ratio, and on this basis, antiviral drugs, antibacterial drugs, antimycotic drugs, antifungal drugs, antimycoplasma drugs and other functional components can be further added. The temperature-sensitive gel is a sustained release preparation with a pH value consistent with the vaginalenvironment, when the temperature is lower than 28 DEG C, the temperature-sensitive gel is in a liquid state, can penetrate into deep folds of the uterus and the vagina and kill pathogens, gel is formed after making contact with the body temperature for 3-5 minutes to cover the disease part, and is not prone to overflowing, and action time and action concentration of the drug and the drug receiving part are guaranteed to the maximum extent; meanwhile, the gel can block the protein synthesis of human papillomavirus (HPV) E6 and E7, and inhibit the proliferation of HPV; and meanwhile, high bactericidal effects on gram-positive bacteria, gram-negative bacteria and fungi are achieved.

A progesterone impregnated vaginal ring/pessary includes a circumferential outer ring composed of a progesterone impregnated biomaterial, wherein the outer ring has a substantially circular configuration while lying flat with an outer diameter of 60 mm to 70 mm and a thickness of approximately 5 mm. The vaginal ring/pessary also includes a transparent membrane extending along an interior space defined by the outer ring. The transparent membrane is composed of a silicone polymer, has a thickness of 1 mm to 3 mm, and includes a plurality of apertures, which are 4 mm to 5 mm in diameter, circumferentially spaced about a perimeter of the transparent membrane.

The invention provides a vaginal acid-base buffer gel and a preparation method thereof, and specifically relates to the pharmaceutical field. The vaginal acid-base buffer gel consists of the followingcomponents (by mass): 1%-39% of an oil phase, 60-99% of a water phase, 0.001-2% of a pH regulator and 0.05-5% of a bacteriostat, wherein the oil phase is white petrolatum or liquid paraffin or glyceryl behenate or Span or Tween or glycerol or propylene glycol; the water phase is hydroxypropyl methylcellulose or carbomer or sodium carboxymethylcellulose or polycarbophil or polyethylene glycol or azone or gelatin or purified water; the pH regulator is citric acid or sodium citrate or sodium hydroxide or hydrochloric acid or triethanolamine or boric acid or borax or sodium dihydrogen phosphate or disodium hydrogen phosphate; the bacteriostat is benzoic acid or sodium benzoate or benzyl alcohol or benzalkonium bromide or benzalkonium chloride or sorbic acid or potassium sorbate or nipalgin. The product prepared by the invention can effectively regulate the original vaginal environment of inflammation, remove vaginal odor and improve symptoms such as increased vaginal secretions or itching.

The invention discloses an oval-body-adjustable gynecological close-range back-loading source applicator, and solves the problems that in the prior art, the source applicator cannot adapt to cervicalcancer patients in various vaginal environments, errors of radiotherapy dosage are easily caused, tumor control fails, and side effects are aggravated. The source applicator comprises a middle connecting frame consisting of a connecting frame main body, and is characterized in that in an elbow mounting hole at the upper end of the middle connecting frame, a source applicator bent is inserted; an oval body left hemisphere and an oval body right hemisphere are symmetrically arranged on the two sides of the middle connecting frame respectively and are each composed of a hemispheric shell, and inwards-concave cavities are formed in the opposite sides of the two hemispheric shells respectively. The oval body left hemisphere and the oval body right hemisphere are connected with the middle connecting frame through the oval body adjusting mechanism. The source applicator is reasonable in design, compact in structure, capable of meeting the treatment requirements of different types of middle and advanced cervical cancer radiotherapy patients, easy and convenient to operate, capable of effectively improving the radiotherapy quality, free of trauma, small in side reaction after treatment, economical, practical and good in patient medical compliance.

The invention relates to the technical field of lubricating fluid, in particular to a medical vagina lubricating fluid and a preparation method thereof. A medical vagina lubricating fluid comprises the following components in percent by weight: 7-15% of glycerinum, 7-16% of almond oil, 3-6% of camellia oil, 1.5-2.3% of sodium carboxymethylcellulose, 2.7-3.2% of water-soluble chitosan, 0.3-0.7% of natamycin, 2-4.5% of vitamin E, 0.15-0.3% of ceramide, 0.4-0.7% of mint oil, and the balance of purified water. According to the invention, the vagina environment can be effectively improved, the lubricating and moisturizing effects can be achieved, the vagina mucosa nerve sensitivity is improved, and the lubricating fluid is sanitary and safe; the use effect is excellent.

The invention relates to a contraceptive, in particular to an intelligent compound gestodene vaginal ring preparation with a memory effect. A vaginal ring consists of a controlled release membrane, a gestodene/ethinyloestradiol-containing carrier and a shape memory material, and can slowly release a contraceptive at constant speed within 21 days. By implementing the preparation, the remarkable contraception effect can be achieved, the inconvenience caused by the oral administration of the contraceptive is avoided, and the appliance of the administration is improved.

The present invention relates to a device for determining intra-abdominal pressure in a subject, comprising an intravaginal ring that is provided with a pressure sensor, means for registering the intra-abdominal pressure value measured by the pressure sensor and means for generating an alert signal when the intra-abdominal pressure exceeds a reference value. The present invention also relates to a method for determining intra-abdominal pressure in a subject, comprising the steps of: a) measuring the intra-abdominal pressure in the vagina by means of a device of the invention, b) comparing the intra-abdominal pressure value measured with a reference value; and c) in case the intra-abdominal pressure value exceeds the reference value transmitting an alert signal to the device that triggers a vibration element in the device or an external device, such as a smartphone or smart watch, to provide a warning to change the subjects behaviour in order to lower the intra-abdominal pressure value.

The invention relates to an intravaginal drug delivery device for hormonal contraception with prevention/reduction of intermenstrual bleeding and menopausal cycle disorders. The intravaginal drug delivery device includes estriol or a precursor of this compound and a progestogen or a precursor thereof.

Disclosed is a vaginal ring containing a ring body made of a first polymeric material having at least one hollow internal channel defining an opening to the exterior of said body and which channel is adapted to receive a drug-containing core through said opening, and a core containing at least one intravaginally administerable drug dispersed in a second polymeric material disposed in the channel. The core is positioned in the vaginal ring body suitably prior to use in order to substantially avoid initial bursts of drug into the tissues of the subject and resultant side effects such as nausea and vomiting. Representative drugs include contraceptive agents and other steroidal substances for use in hormone replacement therapy. Also disclosed are methods for preparing the vaginal rings, kits for assembling the vaginal rings, and methods of using the vaginal rings to achieve intravaginal delivery of drugs to a female.

A variety of different intravaginal drug delivery devices are described for the delivery of estrogens and progestins. The release rate of estrogens and progestins can be controlled by varying the matrix material or by the application of a thin coating. The intravaginal drug delivery devices may be composed of one or more individual compartments. By controlling various physical and chemical parameters, non-zero release rates of the estrogen or progestins may be achieved.